Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol vs Sevoflurane in Breast Cancer Surgery
NCT03005860Withdrawn
- Sponsor
- Tata Memorial Centre
- Start
- Jan 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of propofol in breast cancer, sponsored by Tata Memorial Centre. Primary endpoint: Hypoxia-Inducible Factor 1-alpha at 24 hours. Planned start Jan 2017; status: withdrawn.
02
Drugs
propofol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03005860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005860.